“Asia’s biopharma industry is growing, and growing fast. With technical expertise, low manufacturing costs and improving regulatory frameworks, its value will soon run into the hundreds of billions of dollars. Are you making the most of the opportunity?

Welcome to BioPharma Asia 2016. From humble beginnings as BioMedical Asia in 2008, BioPharma Asia has attracted close to 20,000 attendees over the last 8 years. Established as
a true one-stop shop for all things biopharma, our 2016 program will be bigger than ever before, offering you more tracks, more content and more value. Our 7 premium conference tracks will explore innovation in clinical trials, manufacturing, supply chain, market access, partnering, pricing, vaccines & infectious diseases, antibodies, orphan drugs, biosimilars, stem cells and more.

Our keynote presenters have already confirmed for 2016 and include:

Jun Wang, Founder, Executive Director
Beijing Genome Institute (BGI), China

Kevin Lai
Executive Director – Biomedical Sciences, Singapore Economic Development Board

Niven R. Narain
Co-Founder, President & Chief Technology Officer, BERG Pharma

Prof Zelig Eshhar
Chairman, Department of Immunology
Weizmann Institute of Science, Israel

Bertil Lindmark
Chief Scientific Officer
ASLAN Pharma, Singapore

Ali Miserez
Nanyang Assistant Professor
NRF Fellow, Nanyang Technology University, Singapore

Jin-Hyung Shim
Assistant Professor
Korea Polytechnic University, Korea

Plus we have confirmed over 50 speakers from the following pharmaceutical companies such as:
Janssen | Roche | Eli Lilly | Baxalta | Sphaera Pharma | GSK | Sanofi | Eisai | Berg Pharma | Novartis | ASLAN Pharma | Astra Zeneca | Pfizer | Johnson & Johnson | Merck | PharmAbcine | Roche | Yisheng Biopharma | Global BioPharma (GBP) | AbbVie | MSD | Daiichi-Sankyo | Imugene | Seattle Genetics

And more. Go to www.terrapinn.com/bioasia now! Tiered early bird offers available. Book early and save more!